VANCOUVER, BC — October 29, 2025 — Leads & Copy — VVT Med Inc. (TSXV: VVTM) has secured an initial order for its ScleroSafe™ technology from Northwell Health, a major U.S. healthcare provider.
The order validates the product’s clinical value and marks VVT Med’s entry into the U.S. public hospital market. The technology will be deployed under the direction of Dr. Antonios Gasparis at Northwell Health’s Center for Vein Care.
Northwell Health, based in New York, includes 28 hospitals and over 1,000 clinics. VVT’s solution streamlines varicose vein procedures without anesthetics or capital investment.
According to VVT CEO Erez Tetro, only 2% of symptomatic varicose vein patients seek treatment due to limited solutions and fear of complications. ScleroSafe™ aims to make treatments more accessible and less painful.
VVT Med has also entered investor relations agreements with I3 Capital Group Ltd. and 1001103323 Ontario Inc. (d.b.a Revolution Small Cap Marketing) to enhance market awareness.
I3 will provide corporate communications and marketing strategy services for $55,000 and 400,000 stock options, subject to TSX Venture Exchange approval. Revolution will handle social media engagement for CAD$40,000.
Neither agreement involves related parties or current ownership of VVT Med securities.
Contact:
Erez Tetro, CEO
Source: VVT Med Inc.
